Pacira BioSciences Financial Ratios
NASDAQ: PCRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pacira BioSciences ratio analysis
Pacira BioSciences earned a net margin of 1.0% in FY 2025, up from -14.2% a year earlier. Gross margin was 79.4% compared with a median of 72.7% over the prior 9 years. Return on equity reached 1.0%, meaning Pacira BioSciences generated 0.01 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.54 versus 0.75 the year before, and the current ratio was 4.54. At the end of FY 2025, PCRX traded at 152.9 times earnings; across the 5 fiscal years shown, its year-end P/E ranged from 18.0 to 152.9, with a median of 65.4. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Pacira BioSciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 152.88 | — | 37.91 | 113.56 | 65.40 | 17.97 | — | — | — | — |
| Price / sales | 1.50 | 1.21 | 2.31 | 2.64 | 4.92 | 5.94 | 4.41 | 4.62 | 6.34 | 4.35 |
| Price / book | 1.57 | 1.09 | 1.79 | 2.27 | 3.65 | 4.12 | 5.23 | 4.85 | 6.50 | 5.49 |
| Gross margin | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% | 74.7% | 74.3% | 69.3% | 60.2% |
| Operating margin | 2.6% | -10.5% | 13.0% | 9.0% | 16.6% | 10.8% | 2.5% | 4.7% | -8.7% | -11.6% |
| Net margin | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% | -0.1% | -14.9% | -13.7% |
| Free cash flow margin | 18.8% | 25.5% | 20.7% | 17.3% | 14.7% | 9.1% | 14.3% | 10.2% | -0.5% | 3.2% |
| Return on equity (ROE) | 1.0% | -12.8% | 4.8% | 2.1% | 5.7% | 23.5% | -3.1% | -0.1% | -15.2% | -17.3% |
| Return on assets (ROA) | 0.6% | -6.4% | 2.7% | 0.9% | 2.0% | 11.4% | -1.3% | -0.1% | -6.8% | -9.7% |
| Debt / equity | 0.54 | 0.75 | 0.60 | 0.89 | — | — | — | — | — | 1.04 |
| Current ratio | 4.54 | 2.40 | 5.24 | 3.37 | 1.66 | 2.57 | 3.79 | 7.88 | 6.96 | 5.42 |
| Revenue growth | 3.6% | 3.9% | 1.2% | 23.1% | 26.0% | 2.0% | 24.8% | 17.7% | 3.7% | 11.0% |
| EPS growth | — | -341.6% | 161.8% | -63.0% | -72.4% | — | — | — | — | -2,650.0% |